Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival.
about
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab.Time to progression ratio: promising new metric or just another metric?Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.On the relationship between tumour growth rate and survival in non-small cell lung cancer.
P2860
Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Evaluating Continuous Tumor Me ...... r Predicting Overall Survival.
@ast
Evaluating Continuous Tumor Me ...... r Predicting Overall Survival.
@en
type
label
Evaluating Continuous Tumor Me ...... r Predicting Overall Survival.
@ast
Evaluating Continuous Tumor Me ...... r Predicting Overall Survival.
@en
prefLabel
Evaluating Continuous Tumor Me ...... r Predicting Overall Survival.
@ast
Evaluating Continuous Tumor Me ...... r Predicting Overall Survival.
@en
P2093
P2860
P356
P1476
Evaluating Continuous Tumor Me ...... r Predicting Overall Survival.
@en
P2093
Axel Grothey
Daniel J Sargent
Jan Bogaerts
Jeffrey Meyers
Ming-Wen An
Response Evaluation Criteria in Solid Tumors Steering Committee
Sumithra J Mandrekar
Xinxin Dong
P2860
P356
10.1093/JNCI/DJV239
P407
P577
2015-08-21T00:00:00Z